| Popis: |
Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause psychological distress. Belimumab, a monoclonal antibody that inhibits B-cell activation, is an FDA-approved SLE medication, but less is known on its use in CLE. Moreover, the time to response after starting belimumab in CLE is unknown, which may lead to premature discontinuation in the absence of early perceivable benefits. Thus, objectives of this meta-analysis were to examine: a) the efficacy of belimumab; b) time to response after starting belimumab in patients with CLE with or without SLE.A comprehensive literature search was performed to include studies that examined clinical response in patients with CLE with or without SLE receiving belimumab. Clinical response at 52 weeks in belimumab users vs. non-users was summarized in a random effects model. Additionally, we calculated the pooled odds ratio for each consecutive 4-week observation interval to trend clinical response time in CLE with or without SLE after starting belimumab.Among 747 screened studies, 14 studies were included. Pooled odds of clinical response at 52 weeks in belimumab users were 44% higher compared to non-users (OR 1.44, 95% CI 1.20-1.74, IFindings support belimumab as an effective therapy for CLE with SLE. Likewise, they inform patient counseling regarding estimates of 20 weeks to achieve response. |
Plný text